Results 81 to 90 of about 64,509,941 (193)

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

open access: yesAllergy, Volume 81, Issue 9, Page 3171-3184, September 2026.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama   +16 more
wiley   +1 more source

Eosinophilic granulomatosis with polyangiitis and laryngeal involvement: Review of the literature and a cross-sectional prospective experience

open access: yes, 2018
Background Eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis show variable otorhinolaryngological involvement. Up to 14 per cent of granulomatosis with polyangiitis patients have subglottis involvement; little is known ...
Bartoli, M. L.   +17 more
core   +1 more source

ANCA-associated vasculitis in childhood: recent advances

open access: yesItalian Journal of Pediatrics, 2017
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare systemic diseases that usually occur in adulthood. They comprise granulomatosis with polyangiitis (GPA, Wegener’s), microscopic polyangiitis (MPA) and eosinophilic ...
Marta Calatroni   +20 more
doaj   +1 more source

Remission in Global Airway Diseases: EUFOREA Consensus Paper

open access: yesAllergy, Volume 81, Issue 9, Page 3146-3156, September 2026.
ABSTRACT The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease‐modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR).
J. Christian Virchow   +22 more
wiley   +1 more source

Eosinophilic granulomatosis with polyangiitis induced by montelukast

open access: yesActa clinica Croatica
Leukotriene receptor antagonists are a class of drugs used in maintenance therapy of asthma. Among the adverse effects induced by them, particularly by montelukast, is eosinophilic granulomatosis with polyangiitis (EGPA), which manifests as a form of vasculitis co-occurring with severe asthma and eosinophilia.
Grama, Paul   +4 more
openaire   +3 more sources

Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis

open access: yes, 2020
Blockade of interleukin-5 with reslizumab appears to have significant oral corticosteroid sparing effects in patients with eosinophilic granulomatosis with polyangiitis and severe eosinophilic asthma http://bit.ly/2D2yYSK.
Kent, Brian D   +9 more
core   +1 more source

Tubulointerstitial Nephritis With Uveitis (TINU) Syndrome: A Case Series and Review of Literature

open access: yesNephrology, Volume 31, Issue 9, September 2026.
ABSTRACT Tubulointerstitial nephritis with uveitis (TINU) syndrome is a rare disorder characterised by the simultaneous or sequential occurrence of acute tubulointerstitial nephritis and uveitis, in the absence of systemic disease. Its true prevalence is likely underestimated, as renal and ocular manifestations may not appear concurrently. We conducted
Weaam Ali   +5 more
wiley   +1 more source

Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

open access: yes, 2021
Only a third of patients with eosinophilic granulomatosis with polyangiitis (EGPA) are ANCA-positive, mainly directed against MPO. ANCA directed against PR3 are rarely found in EGPA.
Matthias Papo   +68 more
core   +1 more source

Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

open access: yes, 2016
Conventional treatment of eosinophilic granulomatosis with polyangiitis (EGPA) (Churg-Strauss) with glucocorticoids, with or without additional immunosuppressive drugs, is limited by partial efficacy, frequent toxicity and a high relapse rate.
Hot, A   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy